HealthQuill . Gilead Sciences Inc.
US-based Merck Inc., two late-stage studies have met the main efficacy goal of suppressing the HIV-1 virus in adults receiving different antiretroviral therapies, according to a company statement.
Drugs Health Medical Pharma

Merck’s end-stage studies meet efficacy goal of suppressing HIV-1 virus

US-based Merck Inc., two late-stage studies have met the main efficacy goal of suppressing the HIV-1 virus in adults receiving different antiretroviral therapies,.

Read More
Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a secondary goal of a ‘high’ viral suppression rate in adults.
Drugs Health Pharma

Gilead, Merck’s HIV experimental drug scores ‘high’ on viral suppression

Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.

Read More